--- title: "Clinical Trial Protocol Template" methodology: "universal" complexity: "advanced" owner: "mirichard" updated: "2026-09-19" primary_principles: ["stewardship", "quality-by-design"] secondary_principles: ["evidence-based-decisions"] principle_rationale: "Connects study objectives, endpoints and safety responsibilities to a protocol that qualified scientific and ethics reviewers can evaluate." --- # Clinical Trial Protocol Template ## When to Use - When a clinical research team drafts a protocol for qualified scientific and ethics review. - When objectives, endpoints, study population, and safety responsibilities need a coherent design. ## When NOT to Use - To initiate participant recruitment or procedures without the required approvals. - Do not represent author self-checks as independent or authorized approval. See [Self-approval](../../../../../docs/principles/anti-patterns.md#self-approval). ## Pairs Well With - [Health Authority Communication Plan Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/health_authority_communication_plan_template.md). - [Regulatory Strategy Plan Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_strategy_plan_template.md). Selection context: Delivery domain; universal methodology; advanced complexity. Match the situations above to project phase, risk, team size, and industry using the [decision-engine context model](../../../../../meta/architecture-research/800-801-context-assessment-model.md). Reference check: [Current source](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp). ## Applying this template Treat filled examples, dates, numerical limits, sampling frequencies, and approval outcomes as illustrations. Before execution, replace them with the approved product/site requirements, scientific rationale, method references, responsible reviewer, and acceptance evidence. Record the applicable jurisdiction and current guidance edition; a completed worksheet alone does not demonstrate regulatory compliance. | Requirement or limit | Applicable source / edition | Product-specific rationale | Approval / date | Execution evidence | |---|---|---|---|---| | [Requirement] | [Source] | [Rationale] | [Reviewer / date] | [Record] | This is a protocol-planning worksheet. Map the study to applicable ICH E6(R3) guidance and local requirements, including critical-to-quality factors, participant protection, proportionate risk controls, and sponsor/investigator responsibilities. Protocol approval and compliance require study-specific evidence. ## Document Control | Document Information | Details | |---------------------|---------| | Protocol Title | [TITLE OF THE CLINICAL TRIAL] | | Protocol Number | [UNIQUE IDENTIFIER] | | Protocol Version | [VERSION NUMBER] | | Date of Protocol | [DATE] | | Sponsor | [SPONSOR NAME AND ADDRESS] | | Principal Investigator | [NAME AND AFFILIATION] | | Medical Monitor | [NAME AND CONTACT INFORMATION] | | Amendment History | [TABLE OF AMENDMENTS, DATES, AND BRIEF DESCRIPTIONS] | --- ## 1. Protocol Summary and Administrative Information ### 1.1 Synopsis | Element | Description | |---------|-------------| | Title | [Full title of the clinical trial] | | Phase | [Phase of clinical development (e.g., I, II, III, IV)] | | Study Design | [Brief description of study design, e.g., "Randomized, double-blind, placebo-controlled, parallel-group study"] | | Study Population | [Brief description of the target population] | | Planned Sample Size | [Number of subjects to be enrolled] | | Study Duration | [Expected duration of subject participation and overall study timeline] | | Primary Objective | [Primary objective of the study] | | Primary Endpoint | [Primary endpoint measurement] | | Key Secondary Objectives | [List of key secondary objectives] | | Key Secondary Endpoints | [List of key secondary endpoints] | | Investigational Product | [Name, dose, route, regimen] | ### 1.2 Schedule of Assessments [INSERT TABLE: Comprehensive timeline of all study procedures and assessments across visits] ### 1.3 List of Abbreviations [INSERT TABLE: Alphabetical list of all abbreviations used in the protocol with their definitions] ### 1.4 Protocol Signature Page [Space for signatures of Principal Investigator, Sponsor Representative, and other key stakeholders confirming agreement to conduct the study according to the protocol] --- ## 2. Background and Rationale ### 2.1 Background Information [Provide relevant background information on the disease/condition being studied, including epidemiology, current treatment options, and unmet medical needs] ### 2.2 Preclinical Experience [Summarize relevant preclinical data that supports the clinical investigation, including pharmacology, toxicology, and other relevant non-clinical studies] ### 2.3 Clinical Experience [Summarize relevant previous clinical experience with the investigational product, including completed and ongoing studies, if applicable] ### 2.4 Study Rationale [Explain the scientific rationale for conducting the study, including the risk/benefit assessment and how the study will address scientific questions or unmet medical needs] ### 2.5 Dose Rationale [Provide justification for the dose(s) selected for investigation, including dose-ranging considerations if applicable] ### 2.6 Risk/Benefit Assessment [Discuss potential risks and benefits to trial participants, including risk mitigation strategies] --- ## 3. Trial Objectives and Endpoints ### 3.1 Primary Objective [Clearly state the primary objective of the clinical trial] ### 3.2 Primary Endpoint(s) [Define the primary endpoint(s) that will be used to assess the primary objective, including specific measurement methods and timing] ### 3.3 Secondary Objectives [List all secondary objectives of the clinical trial] ### 3.4 Secondary Endpoints [Define all secondary endpoints that will be used to assess the secondary objectives, including specific measurement methods and timing] ### 3.5 Exploratory Objectives (if applicable) [List any exploratory objectives of the clinical trial] ### 3.6 Exploratory Endpoints (if applicable) [Define any exploratory endpoints, including specific measurement methods and timing] --- ## 4. Trial Design ### 4.1 Overall Design and Plan [Provide a detailed description of the trial design, including a schematic diagram of trial design, procedures, and stages] ### 4.2 Scientific Rationale for Trial Design [Explain the rationale for the chosen trial design elements, including control groups, randomization, blinding, etc.] ### 4.3 Randomization and Blinding #### 4.3.1 Randomization Method [Describe the randomization procedure, including stratification factors if applicable] #### 4.3.2 Blinding Procedures [Describe methods for maintaining the blind, including packaging and labeling of investigational products] #### 4.3.3 Unblinding Procedures [Describe circumstances and procedures for emergency unblinding] ### 4.4 Study Duration [Specify the expected duration of subject participation, description of study stages/periods, and the overall study timeline] --- ## 5. Study Population (Selection and Withdrawal) ### 5.1 Target Population [Describe the general characteristics of the target population] ### 5.2 Inclusion Criteria [List all inclusion criteria that subjects must meet to be eligible for the study] ### 5.3 Exclusion Criteria [List all exclusion criteria that would prevent subjects from participating in the study] ### 5.4 Screening Failures [Define how screening failures will be handled and documented] ### 5.5 Withdrawal/Discontinuation Criteria #### 5.5.1 Reasons for Withdrawal/Discontinuation [List all potential reasons for withdrawal or discontinuation from the study] #### 5.5.2 Handling of Withdrawals [Describe procedures for handling subject withdrawals, including follow-up requirements] #### 5.5.3 Replacement Policy [Specify whether and how withdrawn subjects will be replaced] ### 5.6 Subject Identification and Enrollment [Describe procedures for identifying and enrolling subjects, including the informed consent process] --- ## 6. Treatment/Intervention ### 6.1 Investigational Product(s) #### 6.1.1 Description [Provide detailed description of the investigational product(s), including formulation, packaging, and labeling] #### 6.1.2 Dosage and Administration [Describe the dosage regimen and administration procedures] #### 6.1.3 Dose Modifications [Specify criteria and procedures for dose modifications or adjustments] ### 6.2 Control/Comparator (if applicable) [Provide detailed description of any control or comparator products] ### 6.3 Concomitant Medications #### 6.3.1 Permitted Medications [List medications allowed during the study period] #### 6.3.2 Prohibited Medications [List medications not allowed during the study period] ### 6.4 Treatment Compliance [Describe methods for monitoring and ensuring treatment compliance] ### 6.5 Investigational Product Accountability [Describe procedures for receiving, storing, dispensing, and reconciling investigational products] --- ## 7. Safety Assessment and Reporting ### 7.1 Safety Parameters #### 7.1.1 Vital Signs [Specify vital sign measurements and assessment schedule] #### 7.1.2 Physical Examinations [Describe the scope and frequency of physical examinations] #### 7.1.3 Laboratory Assessments [List all laboratory tests to be performed and assessment schedule] #### 7.1.4 Other Safety Assessments [Describe any other safety assessments, e.g., ECG, imaging, etc.] ### 7.2 Adverse Events #### 7.2.1 Definitions [Provide definitions of adverse events (AEs) and serious adverse events (SAEs)] #### 7.2.2 Assessment and Documentation [Describe procedures for assessing and documenting AEs, including severity and causality assessment] #### 7.2.3 Reporting Requirements [Specify reporting requirements for AEs and SAEs, including timeframes and procedures] ### 7.3 Pregnancy [Describe procedures for handling and reporting pregnancies during the study] ### 7.4 Data Monitoring Committee (if applicable) [Describe the composition, role, and responsibilities of the Data Monitoring Committee] --- ## 8. Data Collection and Management ### 8.1 Source Documents [Define source documents and data to be directly recorded in the CRF] ### 8.2 Case Report Forms [Describe the CRF system to be used (electronic or paper) and procedures for completion and review] ### 8.3 Data Management [Describe data management procedures, including data entry, validation, and query resolution] ### 8.4 Quality Control and Quality Assurance [Describe quality control and quality assurance procedures for the study] ### 8.5 Records Retention [Specify record retention requirements and procedures] ### 8.6 Monitoring [Describe monitoring procedures, including frequency and scope of monitoring visits] --- ## 9. Statistical Methods ### 9.1 Statistical Design [Describe the overall statistical design and analysis plan] ### 9.2 Sample Size Determination [Provide justification for the planned sample size, including assumptions and calculations] ### 9.3 Analysis Populations [Define analysis populations (e.g., intent-to-treat, per-protocol, safety population)] ### 9.4 Statistical Analysis #### 9.4.1 Primary Endpoint Analysis [Describe the statistical methods for analyzing the primary endpoint(s)] #### 9.4.2 Secondary Endpoint Analysis [Describe the statistical methods for analyzing secondary endpoints] #### 9.4.3 Exploratory Analysis (if applicable) [Describe the statistical methods for exploratory analyses] #### 9.4.4 Safety Analysis [Describe the methods for analyzing safety data] ### 9.5 Interim Analysis (if applicable) [Describe any planned interim analyses, including stopping rules and adjusted significance levels] ### 9.6 Handling of Missing Data [Describe methods for handling missing data in the analyses] --- ## 10. Quality Control and Assurance ### 10.1 Data Quality Control [Describe procedures to ensure data quality, including data validation processes] ### 10.2 Study Monitoring [Describe monitoring procedures to ensure protocol compliance and data quality] ### 10.3 Audits and Inspections [Describe procedures for audits and inspections] ### 10.4 Protocol Deviations [Define protocol deviations and procedures for documenting and reporting them] --- ## 11. Ethical Considerations ### 11.1 Regulatory and Ethical Compliance [State the commitment to conduct the study in compliance with applicable regulations and ethical principles] ### 11.2 Institutional Review Board/Independent Ethics Committee [Describe procedures for IRB/IEC review and approval] ### 11.3 Informed Consent Process [Describe the informed consent process, including procedures for obtaining informed consent] ### 11.4 Subject Confidentiality [Describe measures to protect subject confidentiality] ### 11.5 Compensation for Study Participation [Describe any compensation or reimbursement to be provided to subjects] ### 11.6 Study Discontinuation [Describe criteria and procedures for premature termination of the entire study] --- ## 12. Administrative Procedures ### 12.1 Protocol Amendments [Describe procedures for making and implementing protocol amendments] ### 12.2 Protocol Deviations [Describe procedures for handling and reporting protocol deviations] ### 12.3 Publication Policy [Describe the publication policy for study results] ### 12.4 Clinical Study Report [Describe plans and timeline for the clinical study report] ### 12.5 Study Administrative Structure [Provide an overview of the administrative structure for the study, including key roles and responsibilities] --- ## 13. References and Appendices ### 13.1 References [List all references cited in the protocol using a consistent citation format] ### 13.2 Appendices #### Appendix A: Schedule of Assessments [Detailed table of all study procedures by visit] #### Appendix B: Laboratory Tests [Comprehensive list of all laboratory tests with reference ranges] #### Appendix C: Pharmacokinetic Sampling (if applicable) [Detailed schedule and procedures for PK sampling] #### Appendix D: Clinical Trial Governance Structure [Organizational chart showing relationships between sponsor, investigators, and committees] #### Appendix E: Investigational Product Information [Additional details about the investigational product, including chemistry, manufacturing, and controls information as appropriate] #### Appendix F: Assessment Scales and Questionnaires [Copies of any scales or questionnaires to be used in the study] #### Appendix G: Algorithm for Subject Discontinuation [Flowchart or decision tree for subject discontinuation scenarios] --- ## Implementation Notes - This template should be customized for each specific clinical trial protocol - Sections may be added, removed, or modified based on specific trial requirements - All instructions and bracketed placeholder text should be replaced with study-specific information - The protocol should be reviewed by all relevant stakeholders before finalization - Version control should be maintained for all protocol versions and amendments --- *Template Version: 1.0 | Last Updated: [DATE]*